Search
XAV-19
go.drugbank.com/drugs/DB15895InvestigationalThe therapy concept is based on [COVID-19 convalescent plasma]. … Xenothera has partnered with LFB, a pharmaceutical company, to develop XAV-19, and with Nantes University Hospital to test the treatment in patients[L16553,L16558].
Altretamine
go.drugbank.com/drugs/DB00488ApprovedWithdrawnAn alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects.
VSF-173
go.drugbank.com/drugs/DB05753InvestigationalStudy shows that VSF-173 possesses a novel mechanism to address disorders of excessive sleepiness. … It is an oral compound that has demonstrated effects on animal sleep/wake patterns and gene expression patterns suggestive of a stimulant effect.
Lisuride
go.drugbank.com/drugs/DB00589ApprovedAn ergot derivative that acts as an agonist at dopamine D2 receptors (dopamine agonists). It may also act as an antagonist at dopamine D1 receptors, and as an agonist at some serotonin receptors (serotonin agonists).
Synonyms: N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylureaCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEdaxeterkib
go.drugbank.com/drugs/DB21490InvestigationalEdaxeterkib is under investigation in clinical trial NCT03051035 (First-in-Human Study of KO-947 in Non-Hematological Malignancies). Edaxeterkib has a monoisotopic molecular weight of 469.22 Da.
TAK-751S
go.drugbank.com/drugs/DB06432InvestigationalTAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]
Sparsomycin
go.drugbank.com/drugs/DB04222ExperimentalAn antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]
Caprospinol
go.drugbank.com/drugs/DB05263ExperimentalCaprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
OSI-7904L
go.drugbank.com/drugs/DB05457InvestigationalCurrent treatments also inhibit thymidylate synthase but the innovative lipid coating of OSI-7904L allows for more enduring results with administration of the TS inhibitor.